Clinical Trial Results: Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma [Phase 1]

View source ↗

Summary

Phase 1b dose-escalation study of intravenous JX-594 in metastatic, refractory colorectal carcinoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma

Drugs mentioned

• JX-594

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Carcinoma, Colorectal | Phase 1 | Status: COMPLETED | Results posted: 2026-07-08